PROTAC IRAK4 degrader-2

Cat. No.:	HY-135382
CAS No.:	2374122-27-5
Molecular Formula:	$C_{57}H_{68}FN_{11}O_8S$
Molecular Weight:	1086.28
Target:	PROTACs; IRAK
Pathway:	PROTAC; Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

PROTAC IRAK4 degrader-2 (Compound 9) is a PROTAC-based IRAK4 degrader that affords potent IRAK4 degradation with a DC_{50} in peripheral blood mononuclear cells (PBMCs) cells of 151 nM. PROTAC IRAK4 degrader-2 induce a reduction of IRAK4 protein levels with a DC_{50} of 36 nM in PBMC cells. PROTAC IRAK4 degrader-2 also leads to the inhibition of multiple cytokines in PBMCs[1].

In Vitro

PROTAC IRAK4 degrader-2 (compound 9) (0.01~10 μM; 22 hours; PBMCs) mediated degradation is occurring in a proteasome dependent manner[1].

PROTAC IRAK4 degrader-2 (compound 9) (0.01~10 μM; 24 hours; PBMCs) induces a reduction of IRAK4 protein levels[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line:	PBMCs
Concentration:	0.01, 0.03, 0.1, 0.3, 1, 3 and 10 μM
Incubation Time:	22 and 24 hours
Result:	Induced a reduction of IRAK4 protein levels with a DC_{50} value of 36 nM and IRAK4 PROTAC-mediated degradation was occurring in a proteasome dependent manner.

REFERENCES

[1]. Joao Nunes, et al. Targeting IRAK4 for Degradation with PROTACs. ACS Med Chem Lett. 2019 Jun 14;10(7):1081-1085.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA